School of Medicine
Showing 2,231-2,240 of 2,382 Results
-
Chad S. Weldy, M.D., Ph.D.
Instructor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsAs a physician-scientist I work to understand the genetic basis of cardiovascular disease and the transcriptional and epigenomic mechanisms of atherosclerosis. My work is focused across four main areas of cardiovascular genetics and mechanisms of coronary artery disease and smooth muscle biology:
1.Vascular smooth muscle specific ADAR1 mediated RNA editing of double stranded RNA and activation of the double stranded RNA receptor MDA5 in coronary artery disease and vascular calcification
2.Defining on single cell resolution the cellular and epigenomic features of human vascular disease across vascular beds of differing embryonic origin
3.CRISPRi screening with targeted perturb seq (TAPseq) to identify novel CAD genes in human coronary artery smooth muscle cells
4.Investigation of the epigenetic and molecular basis of coronary artery disease and smooth muscle cell transition in mice with conditional smooth muscle genetic deletion of CAD genes Pdgfd and Sox9
My work is focused on discovery of causal mechanisms of disease through leveraging human genetics with sophisticated molecular biology, single cell sequencing technologies, and mouse models of disease. This work attempts to apply multiple scientific research arms to ultimately lead to novel understandings of vascular disease and discover important new therapeutic approaches for drug discovery.
First Author Manuscripts for this work:
•Weldy, C. S., et al. (2025). Smooth muscle cell expression of RNA editing enzyme ADAR1 controls activation of RNA sensor MDA5 in atherosclerosis. (2025). Nature Cardiovascular Research. 1-17, PMID: 40958051, doi: 10.1038/s44161-025-00710-5
•*Selected as finalist for Louis N. and Arnold M. Katz Basic Science Research Prize from the American Heart Association, finalist competition November 16, 2024, Chicago
•Work was highlighted in the Stanford Department of Medicine News
https://medicine.stanford.edu/news/current-news/standard-news/RNA-editing.html
•Weldy, C.S., et al. (2025). Epigenomic landscape of single vascular cells reflects developmental origin and disease risk loci. Molecular Systems Biology. 1-25, PMID: 40931195, doi:10.1038/s44320-025-00140-2.
•*Selected for the cover of November 2025 edition of Molecular Systems Biology
Grant funding received for this work:
Mentored Clinical Scientist Research Career Development Award (K08)(NIH/NHLBI, 1 K08 HL167699-01), August, 2023 – July 2028. PI: Weldy, Chad
•Title of proposal: “ADAR Mediated RNA editing is a causal mechanism in coronary artery disease”.
•Activated 08/01/2023
•$850,000 over 5 years
Career Development Award, American Heart Association (AHA CDA)(23CDA1042900), July, 2023 – June, 2026. PI: Weldy, Chad
•Title of proposal: “Linking RNA editing to coronary artery calcification and disease”
•Activated 07/01/2023
•$231,000 over three years
NIH Loan Repayment Program (LRP) Award (NIH/NHLBI) Renewal Award, July, 2023. PI: Weldy, Chad
•Title of proposal: “RNA editing is a causal mechanism of coronary artery disease”
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) (NIH/NHLBI, 1 F32 HL160067-01), July, 2021 – June 2023 (Completed). PI: Weldy, Chad
• Titled, “A transcriptional network which governs smooth muscle transition is mediated by causal coronary artery disease gene PDGFD”
•*Received perfect score with impact score 10, 1st percentile
NIH Loan Repayment Program (LRP) Award (NIH/NHLBI), July, 2021. PI: Weldy, Chad
•Title of proposal: "Single cell transcriptomic and epigenomic features of human atherosclerosis".
•This will award up to $100,000 towards student loans over the next 24 months with opportunity for renewal after 24 months. -
Kirsti Weng Elder MD/MPH
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Weng is the Section Chief of General Primary Care. She has over 25 years of experience caring for patients in primary care, urgent care and in the hospital. She is also a teacher of students and residents. As a leader in primary care re-design, she is passionate about practicing patient-centered medicine. She is a an advocate of Mindfulness Self-compassion to develop equanimity. She practices with an emphasis on musculoskeletal care as she feels fitness is the foundation of wellness. She is a leader in organizational change and physician management. She supports community health and care for the underserved. Outside of work she enjoys biking, reading and spending time with her 8 children.
-
Wen-Kai Weng, MD, PhD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy research interest is on immunotherapy (including allogeneic transplant) of cancer. I have studies the mechanism of monoclonal antibody therapy in lymphoma patients and am currently working on designing new strategy to enhance the clinical efficacy of antibody therapy by infusing expanded NK cells. I am also interested in using tumor vaccine along with hematopoietic cell transplant.
-
Yingjie Weng
Assistant Director, Learning Health Systems Program, Med/Quantitative Sciences Unit
Current Role at StanfordResponsibilities - Assistant Director, Learning Health Systems Program (LHS)
Program Development & Resource Management
•Establish and update LHS program resources, including standard operating procedures, statistical analysis plan templates, and training materials.
Training & Mentorship
•Host onboarding training programs for new QSU hires and conduct regular training sessions within QSU.
•Establish and mentor a core team of statisticians and data scientists dedicated to the LHS program.
Project Oversight & Strategy
•Guide project assignments related to quality improvement, pragmatic trials, and real-world evidence studies utilizing electronic health records (EHRs).
Collaboration & Relationship Management
•Maintain strong partnerships with clinical advocates of LHS projects across collaborating departments.
•Host onboarding sessions with department leaders to communicate the program’s mission and objectives.
•Establish collaborations with various data teams across campus
Education & Outreach
•Organize educational sessions and lectures for clinical investigators across partnering departments.
•Serve as the primary point of contact for QSU regarding the LHS program.
--------------------------------------------------------------------------------------------------------------------------------
Responsibilities - Senior Biostatistician
Scientific Collaboration & Research Support
•Partner with research investigators on a wide range of scientific studies across the School of Medicine and Stanford Healthcare system.
Study Design & Statistical Planning
•Lead the development of study protocols and statistical analysis plans.
Data Management & Analysis
•Perform data management, visualization, and statistical analysis using advanced methodologies and tools.
Results Interpretation & Reporting
•Interpret statistical results and translate findings into clear, domain-specific language for publications and reports.
Grant & Manuscript Development
•Lead statistical methodology and results sections for grant applications, manuscript submissions, and public health reports.
Methodological Research
•Conduct research on statistical methodologies to enhance study designs and analytical approaches.
Mentorship & Teaching
•Mentor junior statisticians and serve as a KL2 research methodology mentor.
•Deliver lectures, including presentations for Hospital Medicine Grand Rounds. -
Cornelia Weyand
Professor of Medicine (Immunology and Rheumatology), Emerita
Current Research and Scholarly InterestsAutoimmunity
Chronic inflammatory disease
Metabolic control of immune function -
Matthew T. Wheeler
Associate Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsTranslational research in rare and undiagnosed diseases. Basic and clinical research in cardiomyopathy genetics, mechanisms, screening, and treatment. Investigating novel agents for treatment of hypertrophic cardiomyopathy and new mechanisms in heart failure. Cardiovascular screening and genetics in competitive athletes, disease gene discovery in cardiomyopathy and rare disease. Informatics approaches to rare disease and multiomics. Molecular transducers of physical activity bioinformatics.
